FY2024 Earnings Forecast for Valneva Issued By HC Wainwright

Valneva SE (NASDAQ:VALN) – HC Wainwright lowered their FY2024 earnings per share (EPS) estimates for Valneva in a research report issued on Thursday, January 23rd. HC Wainwright analyst E. White now expects that the company will earn $0.13 per share for the year, down from their previous forecast of $0.15. HC Wainwright currently has a “Buy” rating and a $18.00 target price on the stock. The consensus estimate for Valneva’s current full-year earnings is $0.15 per share. HC Wainwright also issued estimates for Valneva’s FY2025 earnings at ($1.29) EPS and FY2026 earnings at ($1.17) EPS.

Valneva Price Performance

VALN stock opened at $4.90 on Monday. Valneva has a one year low of $3.62 and a one year high of $9.50. The firm has a 50-day moving average of $4.29 and a two-hundred day moving average of $5.76. The firm has a market capitalization of $398.17 million, a PE ratio of -37.69 and a beta of 1.93. The company has a current ratio of 2.78, a quick ratio of 2.25 and a debt-to-equity ratio of 0.70.

Institutional Trading of Valneva

A hedge fund recently raised its stake in Valneva stock. AlphaCentric Advisors LLC raised its stake in shares of Valneva SE (NASDAQ:VALN) by 33.7% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 118,000 shares of the company’s stock after buying an additional 29,748 shares during the period. AlphaCentric Advisors LLC owned about 0.15% of Valneva worth $717,000 as of its most recent SEC filing. 11.39% of the stock is currently owned by institutional investors and hedge funds.

About Valneva

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.